Candel Therapeutics (CADL) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on viral immunotherapies for cancer, with lead candidates aglatimagene and linoserpaturev in advanced clinical trials for solid tumors.

• Planning to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate- to high-risk prostate cancer in Q4 2026.

• Positive phase 3 data for aglatimagene in prostate cancer, with statistically significant improvement in disease-free survival and extended follow-up data reinforcing benefit.

• No product sales to date; operations funded by equity and debt, with significant ongoing R&D and commercial readiness investments.

• Mark Sims appointed Chief Commercial Officer to support potential aglatimagene launch.

Financial highlights

• Net loss of $38.9 million for Q2 2026, compared to $4.8 million net loss in Q2 2025, reflecting higher operating expenses and a $12.2 million net other expense related to warrant liabilities.

• Operating expenses rose to $26.7 million in Q2 2026 (up $15.6 million year-over-year), driven by higher clinical development and commercial readiness costs.

• Research and development expenses increased to $19.8 million in Q2 2026 from $7.0 million in Q2 2025, mainly due to higher clinical and manufacturing costs and increased employee expenses.

• General and administrative expenses increased to $6.9 million from $4.2 million year-over-year, mainly from commercial readiness and personnel costs.

• Cash and cash equivalents were $201.6 million as of June 30, 2026, up from $119.7 million at year-end 2025.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2028, including activities for potential aglatimagene commercial launch in 2027; additional capital will be needed for commercialization and further clinical development.

• BLA submission for aglatimagene in prostate cancer planned for Q4 2026; pivotal phase 3 trial in NSCLC initiated in June 2026.

• Anticipated presentation of extended biomarker data at ASTRO Annual Meeting in Q3 2026 and long-term survival data for linoserpaturev in Q4 2026.